Like their normal hematopoietic stem cell counterparts, leukemia stem cells (LSCs) in chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML) are presumed to reside in specific niches in the bone marrow microenvironment (BMM) 1 and may be the cause of relapse following chemotherapy 2 . Targeting the niche is a new strategy to eliminate persistent and drug-resistant LSCs. CD44 (refs. 3,4) and interleukin-6 (ref. 5) have been implicated previously in the LSC niche. Transforming growth factor-b1 (TGF-b1) is released during bone remodeling 6 and plays a part in maintenance of CML LSCs 7 , but a role for TGF-b1 from the BMM has not been defined. Here, we show that alteration of the BMM by osteoblastic cell-specific activation of the parathyroid hormone (PTH) receptor 8, 9 attenuates BCR-ABL1 oncogene-induced CML-like myeloproliferative neoplasia (MPN) 10 but enhances MLL-AF9 oncogene-induced AML 11 in mouse transplantation models, possibly through opposing effects of increased TGF-b1 on the respective LSCs. PTH treatment caused a 15-fold decrease in LSCs in wild-type mice with CML-like MPN and reduced engraftment of immunedeficient mice with primary human CML cells. These results demonstrate that LSC niches in CML and AML are distinct and suggest that modulation of the BMM by PTH may be a feasible strategy to reduce LSCs, a prerequisite for the cure of CML.
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Like their normal hematopoietic stem cell counterparts, leukemia stem cells (LSCs) in chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML) are presumed to reside in specific niches in the bone marrow microenvironment (BMM) 1 and may be the cause of relapse following chemotherapy 2 . Targeting the niche is a new strategy to eliminate persistent and drug-resistant LSCs. CD44 (refs. 3,4) and interleukin-6 (ref. 5 ) have been implicated previously in the LSC niche. Transforming growth factor-b1 (TGF-b1) is released during bone remodeling 6 and plays a part in maintenance of CML LSCs 7 , but a role for TGF-b1 from the BMM has not been defined. Here, we show that alteration of the BMM by osteoblastic cell-specific activation of the parathyroid hormone (PTH) receptor 8, 9 attenuates BCR-ABL1 oncogene-induced CML-like myeloproliferative neoplasia (MPN) 10 but enhances MLL-AF9 oncogene-induced AML 11 in mouse transplantation models, possibly through opposing effects of increased TGF-b1 on the respective LSCs. PTH treatment caused a 15-fold decrease in LSCs in wild-type mice with CML-like MPN and reduced engraftment of immunedeficient mice with primary human CML cells. These results demonstrate that LSC niches in CML and AML are distinct and suggest that modulation of the BMM by PTH may be a feasible strategy to reduce LSCs, a prerequisite for the cure of CML.
Activation of osteoblastic cells in the bone marrow by PTH alters normal hematopoiesis 4 . We therefore tested whether PTH signaling could affect leukemogenesis by using transgenic mice with osteoblastic cell-specific expression of a constitutively active receptor for PTH and PTH-related peptide (PPR) under control of the 2.3 fragment of the collagen type I α1 promoter (Col1-caPPR mice) 8, 9 or wildtype (WT) littermates as recipients in the retroviral transductiontransplantation model of CML-like MPN 12 . In Col1-caPPR recipients, the cumulative mortality due to BCR-ABL1-induced CML-like MPN was significantly decreased (P < 0.001; Fig. 1a ) and overall survival significantly prolonged (P = 0.002, log-rank test; Fig. 1b ) compared to WT recipients, with half of recipients succumbing to histiocytic sarcoma, a BCR-ABL1-induced malignancy of monocyte-macrophages ( Fig. 1b and Supplementary Fig. 1a-f ) that can arise ~2 months after transplantation under conditions where efficiency of induction of CML-like MPN is low 12, 13 . An equivalent number of proviral clones, representing leukemia-initiating cells 4 , engrafted in WT and Col1-caPPR recipient spleen (Fig. 1c) and BM ( Supplementary Fig. 1g ), whereas homing of BCR-ABL1 + c-Kit + Lin − Sca-1 + (KLS) cells to BM and spleen ( Supplementary Fig. 1h ) was not different between Col1-caPPR and WT mice. Yet, counts of circulating leukocytes expressing GFP (coexpressed from the BCR-ABL1-carrying retrovirus) remained normal in most Col1-caPPR recipients at a time (20 d after transplant) when leukocytosis was evident in WT recipients (data not shown, P = 0.03), whereas the absolute number of BM-derived BCR-ABL1 + (GFP + ) KLS cells, defined previously as LSCs in this CML model 14 , was decreased in Col1-caPPR recipients at the time of morbidity or death (P = 0.03, Student's t-test; Fig. 1d ). Therefore, LSCs engrafted but were not maintained in Col1-caPPR recipients.
Rates of LSC apoptosis did not differ (data not shown), but the frequency of cycling GFP + c-Kit + Lin − (KL) cells in Col1-caPPR recipients was significantly decreased (P < 0.001, Student's t-test; Fig. 1e and Supplementary Fig. 1i) , and the number of viable BM cells in leukemic Col1-caPPR recipients was significantly reduced (P < 0.001, Student's t-test; Fig. 1f ) compared to WT recipients. BCR-ABL1-dependent myeloid colony formation 15 was also significantly reduced from Col1-caPPR-derived BCR-ABL1 + BM (P = 0.02, Student's t-test; Fig. 1g ). The survival of WT secondary recipients of BM grafts from leukemic Col1-caPPR donors was significantly prolonged compared to recipients of WT BM grafts (P = 0.04, log-rank test; Fig. 1h ). Together, these results demonstrate that Differential regulation of myeloid leukemias by the bone marrow microenvironment l e t t e r S 1 5 1 4 VOLUME 19 | NUMBER 11 | NOVEMBER 2013 nature medicine BCR-ABL1-induced CML-like disease is attenuated in Col1-caPPR mice owing to decreased frequency, proliferation and maintenance of the phenotypic LSC and leukemic progenitor pool in the BMM. We also transduced WT BM with retrovirus expressing MLL-MLLT3 (here referred to as MLL-AF9), the product of human t(9;11) + AML, which induces aggressive AML in mice 11 . Notably, the survival of Col1-caPPR recipients was significantly shorter than that of WT recipients (P < 0.001, log-rank test; Fig. 1i ). The number of engrafting proviral clones in spleen of Col1-caPPR recipients was significantly increased compared to WT recipients (5.4 ± 1.3 and 3.0 ± 1.1, respectively; P = 0.01, Student's t-test), with similar findings in BM (Fig. 1j) . These results demonstrate that, in contrast to CML-like MPN, MLL-AF9-induced AML is accelerated in Col1-caPPR recipients, possibly owing to an increased number of leukemic clones that engraft and persist in the Col1-caPPR BMM.
As the BMM of Col1-caPPR mice is characterized by increased numbers of osteoclasts and bone remodeling 8 , we treated WT and Col1-caPPR recipients of BCR-ABL1-transduced WT BM with an Fc fusion protein of osteoprotegerin (OPG-Fc), a decoy receptor for receptor activator of nuclear factor κB ligand (RANKL) that can reverse the bone phenotype in Col1-caPPR mice 16 . OPG-Fc treatment significantly increased the frequency of CML-like MPN in Col1-caPPR recipients from 40% to 90% (P = 0.02, chi-square test; Fig. 2a and Supplementary Table 1), but there was not a statistically significant increase in mortality in Col1-caPPR recipients treated with OPG-Fc (P = 0.06, log-rank test; Supplementary Fig. 2a) . Notably, treatment with the osteoclast inhibitor zolendronate did not restore CML-like MPN (data not shown), possibly owing to the distinct mechanisms of OPG-Fc (RANKL antagonism) and zolendronate (inhibition of isoprenoid biosynthesis) on bone remodeling. Col1-caPPR recipients   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22   Probe: GFP   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17 Probe: GFP Anabolic effects of PTH on bone formation during bone remodeling are diminished in Tgfb1 −/− mice 17 . Consistent with this, expression of TGF-β1 protein (Fig. 2b) and biologically active TGF-β1 (P = 0.02, Student's t-test; Fig. 2c ) were increased in the bones of Col1-caPPR compared to WT mice. Whereas the numbers of TGF-β1 + osteoblasts and osteoclasts were increased in Col1-caPPR recipients compared to WT recipients, OPG-Fc treatment eliminated these cells ( Fig. 2d and Supplementary Fig. 2b ) and significantly reduced the amount of nuclear phosphorylated SMAD2/3 (pSMAD2/3), a downstream effector of TGF-β receptor I (TGFBR1), in hematopoietic cells from WT and Col1-caPPR mice with CML (P = 0.004 and P = 0.02, respectively, Student's t-test; Fig. 2e and Supplementary Fig. 2c ). As there was no direct effect of OPG-Fc on BCR-ABL1 + cells in vitro ( Supplementary  Figs. 2d,e) , we hypothesized that increased TGF-β1 signaling in the Col1-caPPR BMM might suppress CML progenitor growth, given that these cells have increased expression of TGFBR1 compared to AML cells (P = 0.027, Student's t-test; Supplementary Fig. 3a-c) 18, 19 . Indeed, TGF-β1 significantly inhibited the in vitro growth of BCR-ABL1 + K562 (CML) but not MLL-AF9 + THP-1 (AML) cells (Fig. 2f) , and direct intrafemoral injection of TGF-β1 in WT recipients with CML-like MPN dramatically reduced BM cellularity (Fig. 2g) .
WT recipients
We further hypothesized that the LSC niche might differ between spleen and BM of Col1-caPPR recipients. In contrast to elevated TGF-β1 in Col1-caPPR bone, TGF-β1 levels in Col1-caPPR spleen were similar to those in WT spleen and bone (Fig. 2h) . We were able to induce CML-like MPN in secondary recipients by transplantation of BM from WT mice or of splenocytes from WT or Col1-caPPR primary leukemic mice, but not by transplantation of Col1-caPPR BM (Fig. 2i) . However, splenectomy of WT or Col1-caPPR primary recipients before transplantation of BCR-ABL1-transduced BM did not affect leukemic mortality ( Supplementary Fig. 3d ), suggesting differential maintenance of LSCs in the BM compared to the spleen of Col1-caPPR mice, possibly owing to different TGF-β1 levels in the respective niches. Taken together, these data support a model in which TGF-β1 generated by increased bone remodeling in Col1-caPPR mice suppresses BCR-ABL1-mediated MPN and may impair the maintenance of LSCs.
To validate this hypothesis, we assessed whether TGF-β1 blockade could increase the incidence of CML in Col1-caPPR recipients. Lentiviral shRNA knockdown of TGFBR1 (to ~60% of control; Supplementary Fig. 4a ) in BCR-ABL1-expressing cells accelerated the development (P = 0.007, log-rank test; Fig. 3a ) and increased the overall incidence (P = 0.04, Fisher's exact test; data not shown) of fatal CML-like MPN in Col1-caPPR recipients relative to control scrambled shRNA lentivirus. Conversely, overexpression of TGFBR1 in MLL-AF9 + AML ( Supplementary Fig. 4b ) resulted in modest but significant prolongation of survival of Col1-caPPR recipients ( Fig. 3b , P = 0.02, logrank and Wilcoxon tests). In response to TGF-β1, nuclear pSMAD2/3 amounts were significantly increased in CML LSCs compared to those in saline-treated cells (P = 0.01, Student's t-test), whereas pSMAD2/3 staining was similar in AML LSCs with and without TGF-β1 treatment ( Fig. 3c,d ). As described previously for CML LSCs 7 , staining for FoxO3a was predominantly nuclear with low phosphorylated AKT npg l e t t e r S kinase staining (Supplementary Fig. 5a ), whereas the percentage of CML LSCs with nuclear pSMAD2/3 was significantly higher in Col1-caPPR than in WT mice (P = 0.02, Student's t-test; Supplementary  Fig. 5b ). These data suggest that TGF-β1 derived from the BMM in Col1-caPPR recipients suppresses CML-like MPN, whereas MLL-AF9-induced AML is insensitive to this effect owing in part to lack of TGFBR1 expression or higher constitutive pSMAD2/3 signaling. Treatment of WT BALB/c mice by continuous infusion of PTH before transplantation of BCR-ABL1-transduced BM caused a transient increase in blood calcium levels 20 (Supplementary Fig. 6a ) and a reduction in splenomegaly (Supplementary Fig. 6b ) but did not alter LSC engraftment (Supplementary Fig. 6c ) or prolong overall survival (data not shown). However, PTH treatment significantly reduced the efficiency of transplantation of CML-like MPN to secondary recipients ( Supplementary Fig. 6d,e increased overall survival of all secondary recipients of BM from PTHtreated donors (P = 0.03, Wilcoxon test; Fig. 4b ), an effect observed in all cohorts except recipients of the lowest cell dose ( Supplementary  Fig. 6f ). Treatment of WT mice with established CML-like MPN ( Supplementary Fig. 7a,b) with imatinib alone or in combination with intermittent infusions of PTH resulted in similar prolongation in survival (P < 0.0001 compared to saline-treated controls; Fig. 4c) , with long-term disease-free survival observed predominantly in the cohort treated with PTH plus imatinib (33% compared to 6% with imatinib alone). PTH treatment, alone or with imatinib, significantly decreased the percentage of cycling KL cells compared to imatinib monotherapy ( Fig. 4d ; P = 0.02 and P = 0.04, respectively, Student's t-test).
To extend these results to human CML, we injected total BM cells (97-100% Philadelphia chromosome-positive by fluorescence in situ hybridization, data not shown) from seven untreated subjects with CML in chronic phase into nonobese diabetic-severe combined immunodeficiency (NOD-SCID) interleukin-2 receptor γc-deficient (NSG) recipient mice pretreated with saline or PTH. Engraftment of human CD45 + leukocytes, assessed in BM aspirates by flow cytometry or estimated by levels of human β-glucuronidase transcripts as determined by quantitative RT-PCR (qRT-PCR) (Supplementary Fig. 7c ), did not differ significantly between saline-and PTH-treated mice (0.2% to 4.8%; Fig. 4e, left) . When we pooled the results from recipients of different subject samples 21 to minimize the known variability of engraftment of human CML cells in immunodeficient mice 22 , PTH treatment was associated with a significant decrease in leukemic engraftment (P = 0.049, Student's t-test; Fig. 4e, right) . These data suggest that modulation of the niche is also deleterious to human CML progenitors, and although conclusions from xenograft studies must be drawn with caution, the results provide some support for testing PTH in human subjects with CML.
In this report, we show that modulation of the BMM can alter the course of leukemia in a physiologically accurate and quantitative mouse model of human CML. We also provide evidence that the LSC niche in MLL-AF9 + AML is distinct from that in CML. Our data suggest that the beneficial effect of PTH in CML is mediated through suppressive effects of TGF-β1, secreted by a BMM characterized by increased bone turnover, on CML LSCs, although we cannot exclude a role for other cytokines induced by PTH signaling. In contrast, the acceleration of MLL-AF9 + AML in Col1-caPPR mice may reflect decreased sensitivity to TGF-β1 or increased size of the niche for AML LSCs. Our findings differ from those of Naka et al. 7 , and this may reflect the known influence of dose and context on the effects of TGF-β1, with supraphysiologic levels of TGF-β1 mediating negative effects on CML LSCs in our model. In conclusion, our results suggest that targeting the hematopoietic microenvironment through PTH may render it hostile for CML cells, raising the possibility of altering the tumor microenvironment as potentially complementary approach to tumor cell-specific therapeutics.
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Methods and any associated references are available in the online version of the paper. 
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Mice. We generated and genotyped Col1-caPPR mice (FVB background) as previously described 8 , using age-and gender-matched WT littermates lacking the transgene as controls. All experimental mice were older than 3 months.
We purchased BALB/c and NOD-SCID interleukin-2 (IL-2) receptor-γ-deficient (NSG) mice from Charles River Laboratories (Wilmington, MA) and Jackson Laboratory (Bar Harbor, ME), respectively. All animal studies were approved by the Institutional Animal Care and Use Committee of Massachusetts General Hospital.
Bone marrow transduction and transplantation. We prepared retroviral stocks as described 4 . We performed BM transplantation as described 11, 12 .
In the CML and AML experiments, we injected 3 × 10 5 or 5 × 10 5 cells, respectively, into irradiated (750 cGy) control or Col1-caPPR mice.
Alternatively to MSCV-IRES GFP BCR-ABL1, we also generated MSCV-IRES RFP BCR-ABL1 or MSCV-IRES RFP Tgfbr1 (cloned into the MSCV-IRES RFP vector as an EcoRI fragment) red fluorescent retrovirus expressing BCR-ABL1 or mouse Tgfbr1. For the generation of lentivirus expressing the Tgfbr1-knockdown or scrambled short hairpin (sh) RNA, we transfected 293 cells with GIPZ scrambled or GIPZ RMM4431-99440663 shRNA (Open Biosystems, Huntsville, AL) and the genes encoding the envelope proteins ∆8.9 and vesicular stomatitis virus G protein. We tested viral supernatants for efficient knockdown of TGFBR1 by qRT-PCR after infection of 3T3 fibroblasts and assessed knockdown of Tgfbr1 in leukemic cells by qRT-PCR of sorted GFP + (GIPZ + lentiviral vector) and RFP + (BCR-ABL1 + ) cells. Tgfbr1-specific primers were 5′-CAGCTCCTCATCGTGTTGGTG-3′ (forward) and 5′-GCCCCTGTTTTTGAAGATGGTG-3′ (reverse).
In homing assays, we transplanted 2.6 × 10 6 5-FU-treated BCR-ABL1-transduced BM cells intravenously into 11 WT and 11 Col1-caPPR mice. 18 h later, we analyzed BM and spleen cells of recipient mice from either genotype by flow cytometry for KLS cells and annexin positivity (Invitrogen, Grand Island, NY) according to the manufacturer's instructions.
For xenotransplantation, we intravenously injected 11 × 10 6 to 50 × 10 6 frozen total BM cells from seven different untreated subjects with CML in chronic phase into one or two irradiated (300 cGy) saline-treated and one or two irradiated PTH-treated NSG mice per subject. Prior fluorescence in situ hybridization had revealed positivity for the BCR-ABL1 translocation in >95% of cells. Saline and PTH treatment by osmotic minipump, as described below, was initiated 4 weeks before xenotransplantation and was continued for 14 weeks thereafter.
In the secondary transplant experiments in the FVB-Col1-caPPR background, we injected 2.5 × 10 6 BM or spleen cells from WT FVB or Col1-caPPR mice on day 19 after primary transplantation with BCR-ABL1 + cells into WT recipients. Flow cytometric analysis of peripheral blood (PB) before harvesting of BM and spleen cells of donor animals revealed fully established CML-like MPN in all donors with a range of 9.9-20.9% CD11b + GFP + cells in the WT donor mice and a range of 19.6-37.7% CD11b + GFP + cells in the Col1-caPPR donor mice. We transplanted BM or spleen grafts from 16 or 10 different individual donors per FVB WT or Col1-caPPR donor group, respectively, into four recipients each, two of which received a BM graft and two a spleen graft.
For the secondary transplantation in the BALB/c background (limiting dilution experiment), we treated primary WT BALB/c mice with saline and human PTH (1-34) by osmotic minipump for 4 weeks before transplantation with BCR-ABL1 + cells. Upon full establishment of CML on day 17, we harvested BM from five saline-treated and five PTH-treated primary animals and pooled the BM within one treatment group. We then transplanted BM from a saline-treated and a PTH-treated BM environment in limiting dilutions of 2 × 10 6 , 1 × 10 6 , 7 × 10 5 , 2 × 10 5 , 7 × 10 4 and 2 × 10 4 cells into five recipients each.
Southern blot analysis. We digested genomic DNA from BM or spleen of leukemic WT or Col1-caPPR mice with the restriction endonuclease BglII, transferred it to nylon membranes and hybridized it with a radioactively labeled probe from the GFP gene in order to detect distinct proviral integration sites. Single-copy DNA represents control DNA from a cell line that contains a single BCR-ABL1 provirus.
TGF-b1 luciferase assay. We transiently transfected Hep3B cells with a TGF-β1-responsive luciferase promoter (CAGA-luc) and a transfection control Renilla luciferase (pRL-TK) vector with Lipofectamine 2000. Forty-eight hours after transfection, cells were serum-starved in 1% FBS Opti-MEM I and then incubated for 16 h with the supernatants from crushed bones from WT or Col-1caPPR mice. As negative and positive controls, cells were incubated with either PBS or 5 ng/ml TGF-β1 (R&D Systems). Experiments were performed in triplicate. Subsequently, we lysed the cells and measured luciferase reporter activity by Dual Reporter Assay (Promega), as described 23 . We determined relative luciferase activity as the ratio of luciferase units to Renilla. Splenectomy. 7 d before transplantation, we anesthetized mice and made an incision below the left ribcage. We then incised the peritoneum aseptically and grasped the spleen. We tied off splenic vessels securely and removed the spleen, subsequently suturing the peritoneum and skin.
Analysis of diseased mice. We diagnosed the different BCR-ABL1-associated diseases in this mouse model, namely CML-like MPN, B cell acute lymphoblastic leukemia (B-ALL) or histiocytic sarcoma and MLL-AF9-induced AML based on clinicopathological criteria, as described 4, 11, 12 . We assessed the leukemic burden in diseased animals weekly by a Vetscan 5 HM (Abaxis, Union City, California) complete blood count analyzer and by staining leukocytes from PB with a phycoerythrin (PE)-conjugated antibody to CD11b (myeloid cells) (clone M1/70, Biolegend, San Diego, CA) in CML-like MPN, a PE-conjugated antibody to BP-1 (clone 6C3/BP-1, BD Biosciences, San Jose, CA) in the case of B-ALL or an allophycocyanin-conjugated antibody to CD11b (clone M1/70, BD Biosciences, San Jose, CA) and a PE-conjugated antibody to Gr-1 (clone RB6-8C5, eBioscience, San Diego, CA) in the case of AML and analysis for expression of GFP (all antibody dilutions were 1:300). We also stained leukocytes with an antibody to TGFBRI (clone ABF17, 1:100, Millipore, Billerica, MA, USA) and a secondary PE-conjugated anti-rabbit-IgG antibody (clone 12-4739-81, eBioscience, San Diego, CA).
By flow cytometry, we analyzed BM aspirates, which we obtained as described 4 , for expression of GFP, Mac-1, Gr-1, lineage (B220, CD5, Gr-1 and Ter119), c-Kit and Sca-1 and for cycling status by Hoechst 33342 (37° C for 30 min) staining on a BD LSRII (Becton Dickinson). We measured cell viability by Trypan blue staining and counting of live cells on a Cellometer Vision (Nexcelom Bioscience LLC, Lawrence, MA).
After obtaining approval from the institutional review board at Massachusetts General Hospital and informed consent from the patients, we assessed engraftment of human cells in NSG mice by flow cytometry using anti-human CD45 (BD Biosciences, Franklin Lakes, NJ). All human samples were deidentified, and gender of subjects is unknown. Human hematopoietic engraftment was also measured by qRT-PCR for human β-glucuronidase (GUS) transcripts (forward primer 5′-GTCTGCGGCATTTTGTCGG-3′ and reverse primer 5′-ACCTCCCGTTCGTACCACA-3′), and a standard curve relating human CD45 expression to human GUS transcripts was used to estimate percentage human engraftment for those samples for which human CD45 was not measured directly. To quantify leukemic engraftment, we performed qRT-PCR for BCR-ABL1 using 5′-GTGCAGAGTGGAGGGAGAAC-3′ (forward) and 5′-ATGCTACTGGCCGCTGAA-3′ (reverse) primers and used these data to estimate the percentage of BCR-ABL1 + cells based on a standard curve (Supplementary Fig. 7 ).
For assessment of the incidence of CML in different transplants, we used the following criteria to define CML: for primary transplants, WBC >15,000/ul and >4% GFP + Mac-1 + cells in PB or death due to CML (hepatosplenomegaly and pulmonary congestion and hemorrhages); for secondary transplants, WBC >10,000/ul or >1% GFP + Mac-1 + cells in PB. We defined AML by the presence of Gr-1 + GFP + myeloid blasts in the PB and massive infiltration of the liver and spleen by these cells.
Histopathology of diseased mice. We took tissue samples of lung, liver, spleen and bone from every deceased mouse and processed, embedded, sectioned and stained them with H&E for histopathological analysis or subjected them to immunohistochemistry analysis for TGF-β1 (clone 66043, Abcam, Cambridge, MA) or pSMAD2/3 (sc-11769, Santa Cruz, Santa Cruz, CA) following standard procedures. We decalcified bones in 0.5 M EDTA. We performed tartrateresistant acid phosphatase (TRAP) staining on bones from the osteoprotegerin npg experiment using 50 mM tartrate in acetate buffer and TRAP reagent in N,N-dimethylformamide, with counterstaining performed with methyl green. A blinded pathologist counted the percentage of hematopoietic cells positive for pSMAD2/3. Drug treatment. We injected 3 mg per kg body weight of rat or human osteoprotegerin-Fc (OPG-Fc) chimera (from E.S.) subcutaneously every other day (three times a week) as described 16 , beginning 1 week before transplantation. We implanted osmotic minipumps (Alzet, Cupertino, CA) as described by the manufacturer. We filled the pumps the previous day with either saline or PTH (resuspended as described 20 ) to allow a daily dose of 80 µg per kg body weight for a total of 14 d, left them in sterile saline at 37° C overnight and changed pumps every 2 weeks. We initiated treatment 4 weeks before transplantation and continued until the animal's death.
For the daily subcutaneous injections (intermittent dosing regimen), we administered human PTH (1-34) or saline at 80 µg per kg body weight per day. We crushed a 100-mg tablet of imatinib, resuspended it in saline, spun, filtered and subcutaneously injected this daily, beginning on day 10 after transplantation.
We performed intrafemoral injections with PBS (left femur) or 250 ng TGF-β1 (right femur) (Sigma-Aldrich, St. Louis, MO) daily on days 15-18 after transplantation of BCR-ABL1-transduced BM into WT FVB recipients.
Western blotting. We crushed and filtered bones or the spleen of a mouse and prepared lysates in RIPA buffer (50 mM Tris Hcl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% NaDOC, 0.1% SDS and 1 mM EDTA), 50 mM NaF, 1 mM Na 3 VO 4 , aprotinin and PMSF. Before loading, we measured the total protein content of lysates by the Bradford dye-binding method (Bio-Rad, Hercules, CA), equalized samples for protein content and boiled them in sample buffer containing DTT. We blotted the proteins onto a PVDF membrane and probed with an antibody to TGF-β1 (clone 2Ar2, 1:1,000, Abcam, Cambridge, MA). We then reprobed the membrane with an antibody to actin (clone H-300, 1:200, Santa Cruz, Santa Cruz, CA). We quantified western blots by ImageJ software by forming the ratio between expression levels of TGF-β1 and the sample's respective actin control.
In vitro assays. We plated K562 or MLL-AF9 + THP-1 cells in sixplicate at 100,000 cells per well of a six-well plate in RPMI with 5 ng/ml TGF-β1 or vehicle. In a separate experiment, we incubated 1 × 10 5 K562 cells with 130 ng/ml OPG-Fc or saline as described 24 and assessed daily for cell number and viability.
For the methylcellulose colony assays, we plated 2 × 10 4 total BM or 2 × 10 5 spleen cells from WT or Col1-caPPR recipients of BCR-ABL1 + -transduced BM on day 21 after transplantation in triplicate in cytokine-free methylcellulose (M3231, Stem Cell Technologies, Vancouver, Canada) supplemented with 100 pg/ml IL-3 (Peprotech, Rocky Hill, NJ). We scored colonies after 10 d. We used serial replating assays in methylcellulose (M3434) for generation of MLL-AF9 + immortalized colony-forming cells for immunofluorescence studies as described 25 .
Immunofluorescence. We prepared cytospin preparations of BCR-ABL1 + or MLL-AF9 + KLS or lineage negative cells, respectively, on poly-l-lysinecovered glass coverslips and stained them for immunofluorescence analysis with anti-pSMAD 2/3, pAkt (clones D6G10 and S473, respectively, Cell Signaling, Danvers, MA) and Foxo3a (clone F2178, Sigma, St. Louis, MO) (all primary antibodies at 1:50), with secondary antibody staining by Alexa Fluor 647-labeled anti-rabbit antibody (1:100, Invitrogen, Grand Island, NY), as described 7 . We visualized the cells by a Nikon Eclipse Ti confocal laser microscope and individually quantitated by ImageJ software.
Serum calcium measurement.
We added plasma to the calcium-detection agent and measured total calcium concentration of PB according to the manufacturer's instructions (Stanbio Laboratory, Boerne, TX).
Statistical analyses.
We determined the statistical significance of the incidence of CML or survival rates in different treatment groups by Fisher's exact or chi-square test. We used L-Calc software (Stemcell Technologies, Vancouver, Canada) to calculate LSC frequency by Poisson statistics.
We assessed differences in survival by Kaplan-Meier nonparametric estimates (log-rank test) and between groups by Student's t-test, with data presented as mean ± s.e.m. P values ≤0.05 were accepted as significant.
